# TABLE OF CONTENTS

## HIGHLIGHTS

5773  
Selected Articles from This Issue

## SPECIAL FEATURES

### CCR Translations

5775  
Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need  
Maliha Nusrat  
See related article, p. 5887

5778  
Protein Glycosylation: “New-yet-Old” Target for Immunotherapy  
Jaydeep Bhat and Dieter Kabelitz  
See related article, p. 5990

### Reviews

5781  
Radiation-induced Adaptive Response: New Potential for Cancer Treatment  
C. Norman Coleman, Iris Eke, Adeola Y. Makinde, Sunita Chopra, Sandra Demaria, Silvia C. Formenti, Shannon Martello, Michelle Bylicky, James B. Mitchell, and Molykutty J. Aryankalayil

5791  
Statins as Anticancer Agents in the Era of Precision Medicine  
Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, and Linda Z. Penn

5801  
Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas  
Javier Martin-Broto, David S. Moura, and Brian A. Van Tine

## PERSPECTIVES

5809  
The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts  
Alex Broom, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, and Mustafa Khasraw

## RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

5814  
Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammapathies: Results of SWOG S0120  
Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits Van Rhee, Bart Barlogie, and Robert Orlovski

## CLINICAL TRIALS: TARGETED THERAPY

5820  
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial  
Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romani, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montañó, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, and Alexí Prat

5830  
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors  

---

Downloaded from clincancerres.aacrjournals.org on August 22, 2021. © 2020 American Association for Cancer Research.
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5952</td>
<td>Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma</td>
<td>Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, and Jeroen de Ridder</td>
</tr>
<tr>
<td>5962</td>
<td>Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer</td>
<td>Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zare Tan, Rui Yamaguchi, and Hiromichi Ebi</td>
</tr>
<tr>
<td>5990</td>
<td>Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors</td>
<td>Sailing Shi, Shengqiu Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng Jhang, Kai W. Wucherpfennig, and X. Shirley Liu</td>
</tr>
<tr>
<td>6003</td>
<td>PD1 Blockade Enhances ICAMI-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer</td>
<td>Katherine D. Gray, Jaclyn E. McCloskey, Yogindra Vedvysa, Olivia R. Kalloo, Steve El Eshaky, Yanping Yang, Enda Shevlin, Majan Zaman, Timothy M. Ullmann, Heng Liang, Dessislava Stefanova, Paul J. Christos, Theresa Scognamiglio, Andrew B. Tassler, Rasa Zannar, Thomas F. Fahey III, Moonsoo M. Jin, and Irene M. Min</td>
</tr>
<tr>
<td>6028</td>
<td>Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma</td>
<td>Daniel W. Sherbenou, Yang Su, Christopher R. Behrens, Blake T. Aftab, Olivia Perez de Acha, Megan Murnane, Shelby C. Bearrows, Byron C. Hann, Jeffery L. Wolf, Thomas G. Martin, and Bin Liu</td>
</tr>
<tr>
<td>6039</td>
<td>Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma</td>
<td>Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yilng Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Miao, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, and Barbara Bedogni</td>
</tr>
<tr>
<td>6051</td>
<td>CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma</td>
<td>Andrew Cannon, Christopher M. Thompson, H. Carlo Maurer, Pranita Atri, Rakesh Bhatia, Sean West, Dario Gerss, Kenneth P. Olive, Sushil Kharo, and Surinder K. Batra</td>
</tr>
<tr>
<td>6064</td>
<td>Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer</td>
<td>Cameron M. Armstrong, Chengfei Liu, Liangren Liu, Joy C. Yang, Wei Lou, Ruining Zhao, Shu Ning, Alan P. Lombard, Jinge Zhao, Leandro S. D’Abramuzo, Christopher P. Evans, Pui-Kai Li, and Allen C. Gao</td>
</tr>
</tbody>
</table>

**AC icon indicates AuthorChoice**

For more information please visit www.aacrjournals.org
ABOUT THE COVER

Multiplex immunofluorescence for PI3K pathway activation on a single cell-level, using formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue on tissue microarrays (TMA). The merged image shows the following markers: PTEN (orange), stathmin (aqua), phosphoS6 (green), p63 (red), AMACR (yellow), and DAPI counterstain (blue) in a TMA core with both normal tissue (center) and invasive tumor tissue. For details, see the article by Stopsack and colleagues on page 5903 of this issue.